was monitored by TLC. Upon completion of the reaction, isolation and purification of the crude products 6(a-n) was carried out by
using above methodology. All the synthesized products are stable, coloured solids and authenticity of these compounds was
established based on their melting points and spectral analysis (IR, 1H NMR and LC-MS).
Spectral data for compound 6(a-n):
(Z)-3-Methyl-1-phenyl-4-(1-phenyl-3-p-tolyl-1H-pyrazol-4-yl)methylene)-1H-pyrazol-5(4H)-one (6a): IR (KBr, cm-1): 3125.7,
1
2982, 1675; H NMR (400 MHz, DMSO-d6/TMS): δ 2.42 (s, 3H, -CH3), 7.38-7.99 (m, 15H, aromatic protons and 1H olefinic
proton), 10.88 (s, 1H pyrazole ring proton); LC-MS: m/z 405 (Q+1).
(Z)-3-Methyl-4-((3-(3-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1-phenyl-1H-pyrazol-5(4H)-one (6b): IR (KBr, cm-1):
1
3539, 312, 3152, 1625, 1590, 778; H NMR (400 MHz, DMSO-d6/TMS): δ 2.30 (s, 3H, -CH3), 7.18-7.96 (m, 14H, aromatic protons
and 1H olefinic proton), 10.60 (s, 1H, pyrazole ring proton); LC-MS: m/z 450 (Q+1).
(Z)-4-((3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (6c): IR (KBr, cm-1):
1
3108, 3072, 2902, 1624, 1573,743; H NMR (400 MHz, DMSO-d6/TMS): δ 2.39 (s, 3H, CH3), 7.20-8.48 (m, 14H, aromatic protons
and 1H olefinic proton), 10.66 (s, 1H, pyrazole ring proton); LC-MS: m/z 439 (Q+1).
(Z)-3-Methyl-1-phenyl-4-((1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)methylene)-1H-pyrazol-5(4H)-one (6d): IR (KBr cm-1): 3128.7,
2985, 1670; 1H NMR (400 MHz, DMSO-d6/TMS): δ 2.30 (s, 3H, -CH3), 3.41(s, 3H, -CH3), 7.26-7.71 (m, 15H, aromatic protons and
1H olefinic proton), 9.22 (s, 1H, pyrazole ring proton); LC-MS: m/z 419 (Q+1).
(Z)-4-((3-(4-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (6e): IR (KBr cm-1):
3125.7, 2982, 1675; 1H NMR (400 MHz, DMSO-d6/TMS): δ 2.34 (s, 3H, -CH3), 7.18-7.14 (m, 14H, aromatic protons and 1H olefinic
proton), 9.25 (s, 1H, pyrazole ring proton); LC-MS: m/z 494 (Q+1).
(Z)-4-((3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (6f): IR (KBr, cm-
1): 3325, 3158, 1620, 1574, 1435; 1H NMR (400 MHz, DMSO-d6/TMS): δ 2.33 (s, 3H, CH3), 3.62 (s, 3H, OCH3), 7.26-7.72 (m, 15H,
aromatic protons and 1H olefinic proton), 9.63 (s,1H pyrazole ring proton); LC-MS: m/z 435 (Q+1).
(Z)-4-((3-(3-Nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1,3-diphenyl-1H-pyrazol-5(4H)-one (6h): IR (KBr, cm-1): 1625,
1
1590, 778; H NMR (400 MHz, DMSO-d6/TMS): δ 7.28-7.71 (m, 20H, aromatic protons and 1H olefinic proton), 9.44 (s, 1H,
pyrazole ring proton); LC-MS: m/z 512 (Q+1).
(Z)-4-((3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1,3-diphenyl-1H-pyrazol-5(4H)-one (6i): IR (KBr, cm-1): 1625,
1
1590, 778; H NMR (400 MHz, DMSO-d6/TMS): δ 7.25-7.91 (m, 20H, aromatic protons and 1H olefinic proton), 9.42 (s, 1H,
pyrazole ring proton); LC-MS: m/z 499 (Q-1).
(Z)-1,3-diphenyl-4-((1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)methylene)-1H-pyrazol-5(4H)-one (6j): IR (KBr, cm-1): 3325, 3158,
1620, 1574, 1435 ; 1H NMR (400 MHz, DMSO-d6/TMS): δ 2.33 (s, 3H, -CH3), 7.25-7.91 (m, 20H, aromatic protons and 1H olefinic
proton), 7.27 (s, 1H, pyrazole ring proton); LC-MS: m/z 481 (Q+1).
(Z)-Ethyl-4-((3-methyl-5-oxo-1-phenyl-1H-pyrazol-4(5H)-ylidene)methyl)-1-phenyl-1H-pyrazole-3-carboxylate (6m): IR (KBr,
1
cm-1): 1720, 1625,1354, 792; H NMR (400 MHz, DMSO-d6/TMS): δ 1.4 (s, 3H, -CH3), 2.4 (s,3H, -CH3), 4.4(s,2H, -CH2), 7.2-7.2
(m, 10H, aromatic protons and 1H olefinic proton), 10.1 (s, 1H, pyrazole ring proton); LC-MS: m/z 399 (Q-1).
(Z)-4-((3-Methyl-5-oxo-1-phenyl-1H-pyrazol-4(5H)-ylidene)methyl)-1-phenyl-1H-pyrazole-3-carboxylic acid (6n): IR (KBr, cm-
1): 3353,1756, 1625,1342, 778; 1H NMR (400 MHz, DMSO-d6/TMS): δ 2.18(s, 3H, -CH3), 7.23-7.84 (m, 11H, aromatic protons and
1H olefinic proton), 10.31 (s, 1H, pyrazole ring proton), 13.10 (s, br, 1H, -COOH D2O exangeble); LC-MS: m/z 371 (Q-1).
Acknowledgement
The authors are very thankful to authorities of Jawaharlal Nehru Technological University for providing laboratory facilities and
they are indebted to University Grants Commission, Govt. of India for providing financial support to one of them (K.V.S) in form of
UGC-SRF scheme.
References
[1]
[2]
[3]
[4]
[5]
[6]
B.F. Wahaba, E. Abdel, H.A. Mohameda, et al., Design and synthesis of new 4-pyrazolin-yl-1,2,3-triazoles and 1,2,3-triazol-4-yl-pyrazolin-1-yl-
thiazoles as potential antimicrobial agents, Eur. J. Med. Chem. 52 (2012) 263-268.
I.V. Magedov, M. Manpadi, S.S. Van, et al., Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic
podophyllotoxin analogues accessible by a one-step multicomponent synthesis, J. Med. Chem. 50 (2007) 5183-5192.
G.C. Rovnyak, R.C. Millonig, J. Schwartz, V.J. Shu, Synthesis and anti-inflammatory activity of hexahydrothiopyrano[4,3-c] pyrazoles and related
analogs, J. Med. Chem. 25 (1982) 1482-1488.
E. Palaska, M. Aytemir, I.T. Uzbay, D. Erol, Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines, Eur. J. Med. Chem. 36 (2001)
539-543.
A. Sener, M.K. Sener, I. Bildmci, R. Kasimogullari, Y. Akcamur, Studies on the reactions of cyclic oxalyl compounds with hydrazines or hydrazones:
Synthesis and reactions of 4-benzoyl-1-(3-nitrophenyl)-5-phenyl-1H-pyrazole-3-carboxylic acid, J. Heterocycl. Chem. 39 (2002) 869-875.
X.H. Liu, P. Cui, B.A. Song, et al., Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3-substituted-4,5-dihydropyrazol-1-
yl)ethanone oxime ester derivatives, Bioorg. Med. Chem. 16 (2008) 4075-4082.
[7]
[8]
E. Akbas, I. Berber, Antibacterial and antifungal activities of new pyrazolo[3,4-d]pyridazin derivatives, Eur. J. Med. Chem. 40 (2005) 401-405.
G.A. Wachter, R.W. Hartmann, T. Sergejew, G.L. Grun, D. Ledergerber, Tetrahydronaphthalenes:ꢀ influence of heterocyclic substituents on inhibition
of steroidogenic enzymes P450 arom and P450 17, J. Med. Chem. 39 (1996) 834-841.